Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004599-23
    Sponsor's Protocol Code Number:GSN00300
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-07
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-004599-23
    A.3Full title of the trial
    A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the
    Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase
    Sperimentazione clinica in doppio cieco, randomizzata, controllata con placebo, per la valutazione dell¿efficacia e della sicurezza di GKT137831 orale in pazienti con colangite biliare primitiva trattati con acido ursodesossicolico e che presentano livelli elevati persistenti di fosfatasi alcalina
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase
    Uno studio per valutare l'efficacia e la sicurezza di GKT137831 in pazienti con colangite biliare primaria riceventi acido ursodesossicolico e con fosfatasi alcalina elevata persistente
    A.3.2Name or abbreviated title of the trial where available
    GSN00300
    GSN00300
    A.4.1Sponsor's protocol code numberGSN00300
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGENKYOTEX SA
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenkyotex Innovation SA
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGenkyotex Innovation SA
    B.5.2Functional name of contact pointIsabelle Aelbrecht
    B.5.3 Address:
    B.5.3.1Street Address516, rue Pierre et Marie Curie
    B.5.3.2Town/ cityLab¿ge
    B.5.3.3Post code31670
    B.5.3.4CountryFrance
    B.5.4Telephone number+33 456 44 81 13
    B.5.5Fax number+33 456 44 81 13
    B.5.6E-mailisabelle.aelbrecht@genkyotex.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code GKT137831
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGKT137831
    D.3.9.2Current sponsor codeGKT137831
    D.3.9.4EV Substance CodeSUB57852
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Biliary Cholangitis
    Colangite biliare primaria
    E.1.1.1Medical condition in easily understood language
    Primary Biliary Cholangitis
    Colangite biliare primaria
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10036680
    E.1.2Term Primary biliary cirrhosis
    E.1.2System Organ Class 100000004871
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of oral GKT137831 in comparison with placebo,
    in subjects with PBC receiving UDCA and with persistently elevated
    Alkaline Phosphatase (ALP).
    Valutare l¿efficacia di GKT137831 orale in confronto a placebo in soggetti con CBP trattati con UDCA e che presentano livelli elevati persistenti di fosfatasi alcalina (ALP).
    E.2.2Secondary objectives of the trial
    To evaluate the safety of oral GKT137831 in comparison with placebo, in subjects with PBC.
    - To estimate the population pharmacokinetics (PK) of GKT137831 and explore any potential Pharmacokinetics-Pharmacodynamics (PK-PD) relationships in this subject population.
    - To explore any relationship between genetic parameters and therapeutic responses in a subset of subjects.
    ¿ Valutare la sicurezza di GKT137831 orale in confronto a placebo in soggetti con CBP.
    ¿ Stimare la farmacocinetica della popolazione di GKT137831 ed esplorare le potenziali correlazioni farmacocinetiche-farmacodinamiche in questa popolazione di soggetti.
    ¿ Esplorare l¿eventuale correlazione tra parametri genetici e risposte terapeutiche in un sottogruppo di soggetti.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female aged 18 to 80 years, inclusive.
    2. Willing and able to give written informed consent and to comply with the requirements of the study.
    3. PBC diagnosis as demonstrated by the presence of = 2 of the following
    3 diagnostic factors:
    o History of elevated ALP levels (> ULN) for at least 6 months
    o Positive anti-mitochondrial antibody (AMA) titer or if AMA negative or in low titer (< 1:80) PBC-specific antibodies (anti-GP210 and/or anti- SP100 and/or antibodies against the major M2 components [PDC-E2, 2- oxo-glutaric acid dehydrogenase complex])
    o Liver biopsy consistent with PBC (based on historic liver biopsy), including non-suppurative, destructive cholangitis affecting mainly the interlobular and septal bile ducts.
    4. Serum ALP = 1.5 x ULN.
    5. Serum GGT = 1.5 x ULN.
    6. UDCA treatment for at least 6 months and stable dose for at least 3 months prior to Visit 1.

    7. Subjects being treated for pruritus with colestyramine must be on a stable dose of colestyramine for at least 8 weeks prior to baseline/Day 1 (Visit 2). Subjects must be willing and able to take colestyramine at
    least 2 hours before or after study medication.
    8. Female subjects of childbearing potential must use a highly effective method of contraception to prevent pregnancy for 4 weeks before randomization and must agree to continue strict contraception for up to 90 days after last administration of investigational medicinal product (IMP). Male participants with female partners of childbearing potential must be willing to use a condom and require their partner to use an additional form of adequate contraception as approved by the Investigator. This requirement begins at the time of informed consent and ends 90 days after the last administration of IMP. Male study participants must also not donate sperm from baseline until 90 days after the last administration of IMP.
    1. Pazienti di entrambi i sessi, di età da 18 a 80 anni inclusi.
    2. Disponibilità e capacità a fornire il consenso informato scritto e a rispettare i requisiti dello studio.
    3. Diagnosi di CBP, dimostrata dalla presenza di =2 dei 3 seguenti fattori diagnostici:
    o Anamnesi di livelli elevati di ALP (>ULN) per almeno 6 mesi
    o Titolo positivo di anticorpi anti-mitocondriali (AMA) o, in caso di titolo AMA negativo o basso (<1:80), anticorpi specifici della CBP (anti-GP210 e/o anti-SP100 e/o anticorpi contro i principali componenti M2 [PDC-E2, complesso ossoglutarato deidrogenasi])
    o Biopsia epatica compatibile con CBP (in base alla biopsia epatica anamnestica), inclusa colangite non suppurativa, distruttiva che colpisce prevalentemente i dotti biliari interlobulari e settali.
    4. ALP sierica =1,5 x ULN.
    5. GGT sierica =1,5 x ULN.
    6. Trattamento con UDCA per almeno 6 mesi e dose stabile per almeno 3 mesi prima della Visita 1.
    7. I soggetti trattati per il prurito con colestiramina devono assumerne una dose stabile per almeno 8 settimane prima del basale/Giorno 1 (Visita 2). I soggetti devono essere disposti e capaci ad assumere colestiramina almeno 2 ore prima o dopo il farmaco dello studio.
    8. Le donne potenzialmente fertili devono utilizzare un metodo contraccettivo altamente efficace per 4 settimane prima della randomizzazione, per prevenire la gravidanza, e devono acconsentire a continuare una contraccezione rigorosa per 90 giorni dopo l’ultima somministrazione del prodotto medicinale sperimentale (IMP). I partecipanti con compagne potenzialmente fertili devono essere disposti a utilizzare il preservativo e richiedere alla loro compagna di utilizzare un ulteriore metodo di contraccezione adeguata, approvata dallo sperimentatore. Questo requisito inizia alla data del consenso informato e termina 90 giorni dopo l’ultima somministrazione dell’IMP. I partecipanti di sesso maschile non devono inoltre donare sperma a partire dal basale e fino a 90 giorni dopo l’ultima somministrazione dell’IMP.
    E.4Principal exclusion criteria
    1. A positive pregnancy test or breast-feeding for female subjects.
    2. Any hepatic decompensation, defined as a past or current history of hepatic encephalopathy, gastrointestinal tract bleeding due to esophageal varices, or ascites
    3. International normalized ratio (INR) > 1.2 unless subject is on anticoagulant therapy.
    4. ALT > 3 x ULN.
    5. Total bilirubin > 1 x ULN.
    6. Planned or current plasmapheresis or other extra-corporeal treatments (e.g., molecular adsorbent recirculation system (MARS)) for treatment-refractory pruritus.
    7. History of liver transplantation, current placement on a liver
    transplant list or current Model for End Stage Liver Disease (MELD) score
    = 15.
    8. Cirrhosis with complications, including history or presence of:
    spontaneous bacterial peritonitis, hepatocellular carcinoma.
    9. Hepatorenal syndrome (type I or II) or Screening serum creatinine > ULN.
    10. Competing etiology for liver disease (e.g., hepatitis C, active hepatitis B, non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), autoimmune hepatitis, primary sclerosing cholangitis, Gilbert's Syndrome).
    11. Subjects receiving prohibited medications within 3 months of
    Screening (Visit 1) according to the list (a, b and c) provided in Section
    6.6.2.
    12. Treatment with any investigational agent within 4 weeks of Visit 1 or
    5 half-lives of the investigational medicinal product (whichever is longer).

    13. A history of long QT syndrome.
    14. Evidence of any of the following cardiac conduction abnormalities during the screening period:
    - A QTc Fredericia interval >450 milliseconds for males and >470 milliseconds for females.
    - A second or third degree atrioventricular block not successfully treated with a pacemaker.
    15. History of cancer in the preceding 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, in situ prostate cancer, in situ breast ductal carcinoma, or superficial bladder cancer stage 0).
    16. The occurrence of any acute infection requiring systemic antibiotic

    therapy within the 2 weeks prior the Screening Visit (Visit 1), or human immunodeficiency virus (HIV) infection.
    17. A history of bone marrow disorder including aplastic anemia, or marked anemia defined as hemoglobin < 10.0 g/dL (or 6.2 mmol/L).
    18. Any condition which, in the opinion of the Investigator, constitutes a risk or contraindication for the participation of the subject in the study, or which could interfere with the study objectives, conduct, or evaluation.
    1. Test di gravidanza positivo o allattamento al seno per i soggetti di sesso femminile.
    2. Qualsiasi scompenso epatico, definito da un’anamnesi pregressa o attuale di encefalopatia epatica, sanguinamento del tratto gastrointestinale dovuto a varici esofagee o ascite.
    3. Rapporto internazionale normalizzato (INR) >1,2 a meno che il soggetto non sia sottoposto a terapia anticoagulante.
    4. ALT >3 x ULN.
    5. Bilirubina totale >1 x ULN.
    6. Plasmaferesi pianificata o attuale oppure altri trattamenti extra-corporei (per es. sistema di ricircolazione assorbente molecolare [MARS]) per il prurito refrattario al trattamento.
    7. Anamnesi di trapianto di fegato, attuale inserimento in una lista di attesa per il trapianto di fegato o punteggio MELD (Model for End Stage Liver Disease, modello per epatopatia in stadio terminale) attuale =15.
    8. Cirrosi con complicazioni, inclusa anamnesi o presenza di peritonite batterica spontanea, carcinoma epatocellulare.
    9. Sindrome epatorenale (tipo I o II) o creatinina sierica allo screening >ULN.
    10. Eziologia competitiva per epatopatia (per es. epatite C, epatite B attiva, steatoepatite non alcolica [NASH], malattia epatica da alcol [ALD], epatite autoimmune, colangite sclerosante primitiva, sindrome di Gilbert).
    11. Soggetti trattati con farmaci non ammessi nei 3 mesi precedenti allo screening (Visita 1) in base all'elenco (a, b, c) alla Sezione 6.6.2.
    12. Trattamento con qualsiasi farmaco sperimentale nelle 4 settimane precedenti alla Visita 1 o nelle 5 emivite del prodotto medicinale sperimentale (a seconda di quale sia il periodo più lungo).
    13. Anamnesi di sindrome del QT lungo.
    14. Evidenza di una qualsiasi delle seguenti anomalie della conduzione cardiaca durante il periodo di screening:
    • Intervallo QTc Fredericia >450 millisecondi per gli uomini e >470 millisecondi per le donne.
    • Blocco atrioventricolare di secondo o di terzo grado, non trattato con successo con un pacemaker.
    15. Anamnesi di neoplasia nei 5 anni precedenti, fatta eccezione per le forme adeguatamente trattate di carcinoma cutaneo non melanomatoso, carcinoma in situ della cervice uterina, carcinoma prostatico in situ, carcinoma mammario duttale in situ o carcinoma superficiale della vescica di stadio 0.
    16. Comparsa di qualsiasi infezione acuta che necessiti di terapia antibiotica sistemica nelle 2 settimane precedenti alla Visita di screening (Visita 1) o infezione da virus dell’immunodeficienza umana (HIV).
    17. Anamnesi di disturbo del midollo osseo, compresa anemia aplastica o anemia marcata definita da emoglobina <10,0 g/dl (o 6,2 mmol/l).
    18. Qualsiasi condizione che, secondo il parere dello sperimentatore, costituisca un rischio o una controindicazione alla partecipazione del soggetto allo studio o che potrebbe interferire con gli obiettivi, la conduzione o la valutazione dello studio.
    E.5 End points
    E.5.1Primary end point(s)
    The percent change from baseline to Week 24 (Visit 7) in serum GGT.
    Variazione percentuale di GGT sierica rispetto al basale alla Settimana 24 (Visita 7).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The percent change from baseline to Week 24 (Visit 7) in serum GGT.
    Serum GGT will be assessed during every treatment visit. (visit's 2-7)

    Variazione percentuale rispetto al basale a 24 settimane (visita 7) nella GGT sierica.
    La GGT del siero sarà valutata durante ogni visita di trattamento. (visita 2-7)
    E.5.2Secondary end point(s)
    - Absolute and percent change in serum GGT from baseline to each assessment.

    - Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to Weeks 12 and 24.

    - Absolute and percent change in serum ALP from baseline to each assessment.

    - Absolute and percent change in serum levels of highsensitivity C- reactive protein (hsCRP) and fibrinogen from baseline to each assessment.

    - Absolute and percent change in serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and conjugated and total bilirubin, from baseline to each assessment.

    - Absolute and percent change in the Fibrosis-4 (FIB-4) and AST to Platelet Ratio Index (APRI) scores, from baseline to each assessment (FIB-4: age (years) x AST (IU/L)/(platelet count (109/L) x (ALT (IU/L)1/2, APRI: AST (IU/L)/ upper normal limit AST)x100/platelet count (109/L).

    - Absolute and percent change in liver stiffness as assessed by transient elastography (FibroScan¿ or similar technology), from baseline to Week
    24, in patients with values at baseline and Week 24.

    - Absolute and percent change in serum levels of collagen fragments indicative of collagen formation and degradation from baseline to Weeks
    12 and 24.

    -Absolute and percent change in total bile acids from baseline to Week
    12 and 24.
    ¿ Variazione assoluta e percentuale della GGT sierica rispetto al basale a ciascuna valutazione.
    ¿ Variazione assoluta del punteggio ELF (Enhanced Liver Fibrosis, fibrosi epatica avanzata) rispetto al basale alle Settimane 12 e 24.
    ¿ Variazione assoluta e percentuale dell¿ALP sierica rispetto al basale a ciascuna valutazione.
    ¿ Variazione assoluta e percentuale dei livelli sierici di proteina C reattiva ad alta sensibilit¿ (hsCRP) e fibrinogeno, rispetto al basale a ciascuna valutazione.
    ¿ Variazione assoluta e percentuale dei livelli sierici di alanina aminotransferasi (ALT), aspartato aminotransferasi (AST), bilirubina coniugata e totale, rispetto al basale a ciascuna valutazione.
    ¿ Variazione assoluta e percentuale dei punteggi FIB (Fibrosis-4, fibrosi 4) e APRI (AST to Platelet Ratio Index, indice di rapporto tra AST e piastrine), rispetto al basale a ciascuna valutazione (FIB-4: et¿ (anni) x AST (UI/l)/(conta piastrinica (109/l) x (ALT (UI/l)1/2, APRI: AST (UI/l)/AST limite superiore della norma)x100/conta piastrinica (109/l).
    ¿ Variazione assoluta e percentuale della rigidit¿ epatica, valutata con elastografia transitoria (FibroScan¿ o tecnologia simile), rispetto al basale alla Settimana 24, in pazienti con valori al basale e alla Settimana 24.
    ¿ Variazione assoluta e percentuale dei livelli sierici di frammenti di collagene indicativi di formazione di collagene e relativa degradazione, rispetto al basale alle Settimane 12 e 24.
    ¿ Variazione assoluta e percentuale degli acidi biliari totali, rispetto al basale alle Settimane 12 e 24.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Timepoints of the secondary endponts are included within the secondary objective endpoints section E.5.2 (above)

    Most secondary assessments will be assessed from baseline to each visit however the ELF score and collagen fragments will be assessed from baseline to week 12 and week 24.
    The change in liver stiffness (FibroScan¿ or similar technology) will be assessed from baseline to week 24.
    I timepoints degli endpoint secondari sono inclusi nell'ambito degli endpoint dell'obiettivo secondario sezione E.5.2 (sopra)
    ¿
    La maggior parte delle valutazioni secondarie saranno valutate rispetto al basale a ciascuna visita, tuttavia il punteggio ELF e i frammenti di collagene verranno valutati rispetto al basale alla settimana 12 e alla settimana 24.
    La variazione della rigidit¿ del fegato (FibroScan¿ o tecnologia simile) sar¿ valutata rispetto al basale alla settimana 24.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    United States
    Belgium
    Germany
    Greece
    Italy
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 95
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 7
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 102
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-02-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-11-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-04-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 15:35:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA